Cellcolabs’ €10.3M Funding Targets 90% Stem Cell Cost Reduction
Stockholm-based Cellcolabs has raised €10.3 million to revolutionize stem cell accessibility through scalable manufacturing. The funding signals growing investor confidence in making regenerative medicine affordable and widely available. This could transform how research and therapies are developed